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ISSUES IN MEDICINE
High uptake of HIV testing for tuberculosis patients in an 
integrated primary health care HIV/TB programme in rural 
KwaZulu-Natal
Claudia Wallrauch, Tom Heller, Richard Lessells, Mmabatho Kekana, Till Bärnighausen, Marie-Louise Newell
Tuberculosis (TB) is the leading cause of morbidity and 
mortality in the HIV-infected African population. The need for 
improved integration of HIV and TB services was highlighted 
by the World Health Organization (WHO) several years ago, 
but implementation of recommendations has been slow.1,2 HIV 
testing for TB patients is the gateway for combined HIV and 
TB treatment, care and prevention yet, in 2007, only 37% of TB 
patients in the WHO African region were tested for HIV.3 While 
some countries reported testing rates above 75%, a testing rate 
of only 39% was reported in South Africa, the country with 
the largest burden of HIV/TB co-infection.3 We describe our 
efforts to ensure high HIV testing rates in TB patients via an 
integrated programme at primary health care level in rural 
KwaZulu-Natal.
Methods
Hlabisa Hospital is a 300-bed district hospital in northern 
KwaZulu-Natal. The hospital and its 17 primary health 
care clinics serve a population of 228 000. In 2008, the TB 
notification rate was approximately 1 700/100 000 population. 
Antenatal HIV seroprevalence was 37.7% in 2005.4 In the 
peripheral clinics, TB nurses identify TB suspects, send sputum 
for acid-fast bacilli (AFB) smear testing, and initiate treatment 
for uncomplicated smear-positive cases. In each clinic, the HIV 
Treatment and Care Programme team is responsible for HIV 
testing, CD4 count measurement, and initiation and monitoring 
of antiretroviral therapy (ART). HIV-infected individuals 
undergo standardised TB screening prior to initiation of ART.
A TB/HIV integration plan was implemented in March 2008, 
with four key components:
1.    Close physical proximity of the TB and HIV teams in the 
hospital and local clinics (through facilities shared by HIV 
and TB programme staff) to facilitate patient flow (Fig. 1).
2.    Introduction of a central TB clinic on the hospital premises 
for referral of smear-negative and extrapulmonary TB 
suspects. The protocol for this clinic included clinical 
evaluation by the TB nurse, TB culture (as appropriate), 
chest X-ray, ultrasound, HIV counselling and testing, and 
assessment by a physician with diagnosis based on clinical 
and radiological features.
3.    A programme of training for TB health care workers in 
HIV-related topics and for HIV staff in TB-related topics 
(covering the essentials of clinical presentation, diagnosis, 
and treatment of HIV and TB).
4.    Development of a Microsoft Access database to store basic 
demographic and clinical data relating to TB and HIV. All 
data were extracted from the National Tuberculosis Control 
Programme patient cards. The database was used for 
monitoring and evaluation, a critical aspect of which was 
regular feedback to each clinic on HIV testing uptake.
The analysis includes all patient data entered into the 
database from March 2008 to February 2009 (pilot period 
with incomplete data March - May 2008). Statistical analyses 
were performed using SPSS 15.0 (SPSS Inc., Chicago). Ethical 
approval for retrospective analysis of data was granted by the 
Hlabisa Hospital ethics committee.
Results
Included in the analysis were 2 953 patients (53% female) who 
received treatment in the TB programme between March 2008 
and February 2009. Seventy-one per cent (95% confidence 
interval (CI) 69 - 73%) started regimen 1 (rifampicin (R), 
isoniazid (H), pyrazinamide (Z), and ethambutol (E) for 2 
months followed by 4 months RH; for adult patients with 
newly diagnosed TB); 13% (95% CI 12 - 14%) were placed on 
regimen 2 (RHZE + streptomycin (S) for 2 months, RHZE for 
1 month, then RHE for 5 months; for adult re-treatment cases); 
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Fig. 1. Park homes shared by TB and HIV services in peripheral primary 
health care clinics. Waiting areas are in the shaded open air to reduce TB 
transmission risk.
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2% (95% CI 1 - 3%) received multidrug-resistant (MDR) TB 
treatment; and 15% (95% CI 14 - 16%) were children <8 years 
old (treated with RHZ for 2 months followed by RH for 4 
months). Cases were categorised as follows: pulmonary TB 
(PTB) for 2 805 patients (95% (95% CI 94 - 96%)), of whom 
454 (16% (95% CI 15 - 17%)) were recorded as sputum smear-
positive, and 2 351 (84% (95% CI 83 - 85%)) were smear-
negative. Extrapulmonary TB (EPTB) was recorded in only 148 
patients (5% (95% CI 4 - 6%)).
HIV testing uptake was analysed monthly. After the initial 
training period, the proportion of patients with known HIV 
status at all clinics combined was 81% and, from additional 
training and feedback, this rate had increased to 88% by 
February 2009. In total, there were 2 596 patients with known 
HIV status (88% (95% CI 87 - 89%)). Overall HIV prevalence 
was 76% (1973/2 596 (95% CI 74 - 78%)). HIV prevalence was 
higher for females than males (81% v. 71%, p<0.001). HIV 
prevalence was also significantly higher among re-treatment 
than new patients (88% v. 78%, p<0.001). CD4 counts were 
recorded for 1 610 patients (81% of HIV-infected): 83% (95% CI 
81 - 85%) had CD4 counts <350 cells/µl, 62% (95% CI 60 - 64%) 
<200 cells/µl, and 20% (95% CI 18 - 22%) <50 cells/µl.
Discussion
Our finding that the majority of patients seeking treatment in 
a public sector TB programme are HIV-infected highlights the 
close connection between the two epidemics in South Africa. 
Sustainable solutions for the integration of decentralised TB 
and HIV services at primary health care level are necessary, 
not only to deal with the overwhelming burden of co-infected 
individuals but also to implement HIV and TB prevention 
interventions. Our experience suggests that high rates of 
HIV testing and enrolment in HIV care can be achieved by 
relatively simple measures. Physical proximity of TB and HIV 
services facilitates patient flow, reduces loss of patients, and 
improves communication between staff members. Training for 
nurses and counsellors in the TB and HIV programmes, with 
performance monitoring and regular feedback, should ensure 
high rates of HIV testing.
Some sub-Saharan African countries have reported similarly 
high rates of HIV testing in TB patients5 but, in South Africa, 
even in research settings, testing rates have generally been 
reported to be lower.6 We have demonstrated that there is 
no specific barrier to achieving high testing rates, and that 
relatively simple but sustainable solutions can be implemented 
within the existing primary health care system in rural South 
Africa. We have also shown relatively high rates of CD4 testing 
in co-infected individuals, with the majority eligible for ART 
under WHO guidelines. Future analyses will be directed at 
determining ART uptake and long-term retention of co-infected 
individuals.
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